The cellular origins of drug resistance in cancer
Top Cited Papers
- 3 March 2016
- journal article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 22 (3), 232-234
- https://doi.org/10.1038/nm.4058
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cellsNature Communications, 2016
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionNature Medicine, 2016
- Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung CancerCancer Discovery, 2015
- AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNAClinical Cancer Research, 2014
- High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation: Truth or Artifact?Journal of Thoracic Oncology, 2013
- Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingScience Translational Medicine, 2011
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based AssayClinical Cancer Research, 2011
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007